Stock listing
Intellia Therapeutics, Inc.
- Ticker
- Munich:38I
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- Munich
- Currency
- EUR
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a public biotechnology company based in the United States, focused on developing innovative gene editing therapies. Intellia is dedicated to advancing its research and development efforts in the field of genetic medicine.
Latest news from Intellia Therapeutics, Inc.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Sep 8, 2026
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Sep 4, 2026
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Sep 4, 2026